Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Nov 2;17(11):e0275522.
doi: 10.1371/journal.pone.0275522. eCollection 2022.

The effects of reduced nicotine content cigarettes on biomarkers of nicotine and toxicant exposure, smoking behavior and psychiatric symptoms in smokers with mood or anxiety disorders: A double-blind randomized trial

Affiliations
Randomized Controlled Trial

The effects of reduced nicotine content cigarettes on biomarkers of nicotine and toxicant exposure, smoking behavior and psychiatric symptoms in smokers with mood or anxiety disorders: A double-blind randomized trial

Jonathan Foulds et al. PLoS One. .

Abstract

Background: The U.S. Food and Drug Administration and the government of New Zealand have proposed a reduction of the nicotine content in cigarettes to very low levels. This study examined the potential effects of this regulation in smokers with affective disorders.

Methods: In a randomized controlled parallel group trial conducted at two sites in the USA (Penn State University, Hershey, PA and Massachusetts General Hospital, Boston, MA) 188 adult smokers with a current (n = 118) or lifetime (n = 70) anxiety or unipolar mood disorder, not planning to quit in the next 6 months, were randomly assigned (1:1) to smoke either Usual Nicotine Content (UNC) (11.6 mg nicotine/cigarette) research cigarettes, or Reduced Nicotine Content (RNC) research cigarettes where the nicotine content per cigarette was progressively reduced to 0.2 mg in five steps over 18 weeks. Participants were then offered the choice to either receive assistance to quit smoking, receive free research cigarettes, or resume using their own cigarette brand during a 12-week follow-up period. Main outcomes were biomarkers of nicotine and toxicant exposure, smoking behavior and dependence and severity of psychiatric symptoms. The pre-registered primary outcome was plasma cotinine.

Results: A total of 143 (76.1%) randomized participants completed the randomized phase of the trial, 69 (73.4%) in the RNC group and 74 (78.8%) in the UNC group. After switching to the lowest nicotine content cigarettes, compared to smokers in the UNC group, at the last randomized visit the RNC group had significantly lower plasma cotinine (metabolite of nicotine): difference between groups, -175.7, 95% CI [-218.3, -133.1] ng/ml. Urine NNAL (metabolite of NNK, a lung carcinogen), exhaled carbon-monoxide, cigarette consumption, and cigarette dependence were also significantly lower in the RNC group than the UNC group. No between-group differences were found on a range of other biomarkers (e.g. 8-isoprostanes) or health indicators (e.g. blood pressure), or on 5 different psychiatric questionnaires, including the Kessler K6 measure of psychological distress. At the end of the subsequent 12-week treatment choice phase, those randomized to the RNC group were more likely to have quit smoking, based on initial intent-to-treat sample, n = 188 (18.1% RNC v 4.3% UNC, p = 0.004).

Conclusion: Reducing nicotine content in cigarettes to very low levels reduces some toxicant exposures and cigarette addiction and increases smoking cessation in smokers with mood and/or anxiety disorders, without worsening mental health.

Trial registration: TRN: NCT01928758, registered August 21, 2013.

PubMed Disclaimer

Conflict of interest statement

JF has done paid consulting for pharmaceutical companies involved in producing smoking cessation medications, including GSK, Pfizer, Novartis, J&J, and Cypress Bioscience, and received a research grant from Pfizer Inc (not related to reduced nicotine cigarettes). AEE reports grant support to her institution from subcontracts from NIDA grants to Charles River Analytics and Brain Solutions LLC and consulting fees from Karuna Pharmaceuticals and Alkermes and editorial support from Pfizer for papers arising from the EAGLES trial. There are no competing interests to declare for other authors. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. CONSORT participant flow diagram.
Fig 2
Fig 2
2A-2D. Changes in plasma cotinine, exhaled CO, daily cigarette consumption, and FTND nicotine dependence score among completers (n = 143) smoking either Usual Nicotine Content (n = 74) cigarettes or Reduced Nicotine Content (n = 69) cigarettes. * indicates statistically significant between group difference at Visit 10, controlling for Visit 4 baseline.
Fig 3
Fig 3
3A-3D. Changes in OASIS, QIDS, PSS, and NNAL# among completers (n = 143) smoking either Usual Nicotine Content (n = 74) cigarettes or Reduced Nicotine Content (n = 69) cigarettes. * indicates statistically significant between group difference at Visit 10, controlling for Visit 4 baseline. # urine NNAL measured in randomly selected subgroup (n = 26 on RNCs and n = 25 on UNCs, evenly stratified by site and by study group), who provided urine samples at randomization (v4) and at the end of the randomized phase of the trial (v10).
Fig 4
Fig 4. The proportion of participants initially randomized to reduced nicotine content or usual nicotine content cigarettes who had quit smoking cigarettes at visit 11, and at visit 12.
*p<0.01 for comparison between proportion randomized to RNC and UNC group who reported no cigarettes smoked in the previous week with exhaled CO<10ppm.

Similar articles

Cited by

References

    1. Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. The Health Consequences of Smoking-50 Years of Progress: A Report of the Surgeon General. Reports of the Surgeon General. Atlanta (GA) 2014.
    1. Gottlieb S, Zeller M. A Nicotine-Focused Framework for Public Health. N Engl J Med. 2017;377(12):1111–4. doi: 10.1056/NEJMp1707409 - DOI - PubMed
    1. Food and Drug Administration. FDA Announces Plans for Proposed Rule to Reduce Addictiveness of Cigarettes and Other Combusted Tobacco Products 2022. June 21 [cited 2022 August 29]. Available from: https://www.fda.gov/news-events/press-announcements/fda-announces-plans-....
    1. New Zealand Ministry of Health. Smokefree Aotearoa 2025 Action Plan—Auahi Kore Aotearoa Mahere Rautaki 2025. In: Ministry of Health, editor. Wellington: New Zealand Ministry of Health; 2021.
    1. Apelberg BJ, Feirman SP, Salazar E, Corey CG, Ambrose BK, Paredes A, et al. Potential Public Health Effects of Reducing Nicotine Levels in Cigarettes in the United States. New England Journal of Medicine. 2018;378(18):1725–33. doi: 10.1056/NEJMsr1714617 - DOI - PubMed

Publication types

Associated data